Comparison of caspofungin and amphotericin B for invasive candidiasis.

By Jorge Mora-Duarte, R. Betts, C. Rotstein, A. Colombo, Luis Thompson-Moya, Juanita M. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, J. Perfect. New England Journal of Medicine, 2002

1,238 citations recorded by the source corpus.

Subfields: Infectious Diseases, Parasitology

View Paper: https://www.semanticscholar.org/paper/374f243b941688040a55fcec2d5f8ad60ef9435e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

Citations in the corpus

Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America (2009, background): “krusei), echinocandins (caspofungin administered with a 70-mg intravenous loading dose, followed by 50 mg daily administered intravenously; micafungin at a dosage of 100 mg daily administered intravenously or anidulafungin with a 200-mg intravenous loading dose followed by 100 mg daily administered ”
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “…pregnancy $14 d after last positive blood culture Receipt of $1 d of antifungal drug Clinical and microbiologic success at EOT All-cause death at EOT Mora-Duarte et al, 2002 [48] (239; 1997–2001) Caspofungin 50 mg/d vs amphotericin B 0.6–0.7 mg/kg/d (0.7–1.0 for neutropenic patients) Randomized,…”
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “in randomized, comparative clinical trials [24–28, 31, 32].”
Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “113.”
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (2005, background): “didemia are more conservative than those of prior retrospective studies [910–11, 17] but accord with estimates generated with prospectively collected data from 2 randomized clinical trials of therapy for invasive candidiasis [18, 19 ].”
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004, result): “study were similar to those found in comparative therapeutic trials of esophageal candidiasis and candidemia [30, 31, 37],”
Attributable mortality of nosocomial candidemia, revisited. (2003, background): “Prospective clinical trials also estimate the mortality attributable to candidemia to be much lower than those observed with our retrospective cohort design (5%–7% [7, 21] vs.”
Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, methodology): “Among the Candida species, C. parapsilosis and Candida guilliermondii isolates have higher MIC values than do C. albicans isolates, although the clinical signiﬁcance of this reduced in vitro susceptibility has been debated [83].”